Skip to content

Short squeeze alert for August 24th: Two stocks poised for lift off

Short squeeze alert for August 24th: Two stocks poised for lift off
Kliment Dukovski

Trading heavily shorted stocks can be a profitable strategy. That’s because to short a stock, a trader has to borrow it first and then sell it on the market, hoping to profit as the stock price goes down. If the stock starts going up, it will likely force the ‘shorts’ to buy back and cover their positions. This is known as a short squeeze and often pushes the stock price beyond real valuation.

Because the interest for shorted stocks remains, Finbold analyzed the most shorted stocks this year and selected the two with a high potential to soar.

Enovix (NASDAQ: ENVX)

Enovix Corporation is a silicon battery company that designs, develops, and manufactures silicon-anode lithium-ion batteries using a 3D cell architecture. Its batteries are used on wearables, mobile devices, laptops, and augmented reality eyewear.

The company stock is among the top 10 most shorted, with 28% of float.

Meanwhile, Morningstar’s quantitative equity report has put a fair value estimate at $23.76 for ENVX. That’s 71% above the current market price of $13.89. If ENVX reaches Morningstar’s target price, it is likely to start the short squeeze.

Morningstar quantitative equity report for ENVX. Source: Interactive Brokers Fundamentals Explorer

ChargePoint (NYSE: CHPT)

ChargePoint Holdings is an electric vehicle charging technology solutions provider. The company sells charging hardware connected through cloud-based software to customers to enable charging station owners to manage their network of charging systems.

The company shares are shorted 24.79% of the float. This percentage is similar to what we had throughout the whole year.

ChargePoint’s next earnings release is on September 6, 2023, which could provide some clues about where the stock price may go next. Analysts expect the company to post earnings of -$0.14 per share, a 26.32% year-over-year growth.

Morningstar’s quantitative equity report puts a $11 fair value on the stock price, which is 55% above the current market price of $7.07.

Morningstar quantitative equity report for CHPT. Source: Interactive Brokers Fundamentals Explorer

Shorting the stock has had a negative effect on ChargePoint as it’s down 22% year to date. Enovix, on the other hand, has proven more resilient, being up 14% during the same period. Both have underperformed the S&P 500’s 16% return, though.

Buy stocks now with Interactive Brokers – the most advanced investment platform

Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Services

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.